CELZ — Creative Medical Technology Hol

Is CELZ overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Creative Medical Technology Hol (CELZ) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.52. The rating moved from Neutral to Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

Creative Medical Technology Hol (CELZ) is a microcap healthcare issuer trading at low absolute price and exhibiting limited public disclosure, which constrains fundamental analysis. Price behavior is likely to be driven by episodic, binary events (clinical, licensing, or financing news) and by speculative flows rather than steady operational performance. The current market environment—risk-on into earnings—can support short-term speculative interest, but sector leadership is concentrated in large-cap pharma and defensive healthcare, limiting sustained capital rotation into very small names. Primary concerns are an opaque financial position, likely need for future financing, and low liquidity that amplify downside on negative news. Near-term scenarios include short-term spikes on positive headlines or stepwise declines if dilution or weak disclosures surface; absent clear, verifiable fundamental improvements, directional moves are likely to remain driven by sentiment and corporate-specific announcements.

Key factors

  • Microcap / penny-stock status with current price near $0.52 implies high volatility and limited liquidity
  • No recent EDGAR filings or detailed public financial disclosures available, making fundamentals hard to verify
  • Potential upside tied to binary catalysts (clinical updates, licensing, or partnership announcements) common for small healthcare issuers
  • Broader market tone is risk-on into earnings, which can temporarily lift speculative healthcare names
  • Sector flows currently favor large-cap pharma and defensive healthcare, which may limit investor appetite for microcap therapeutics
  • History of dilution pressure in small-cap biotech/diagnostics sector increases likelihood of future financings

Risks

  • Very limited public financial information and absence of up-to-date filings increases uncertainty about cash runway and liabilities
  • High probability of equity dilution through financings or convertible instruments, eroding shareholder value
  • Low float and poor liquidity can lead to sharp, unpredictable price moves and wide bid-ask spreads
  • Regulatory or clinical setbacks (if applicable to company products) would be materially negative given small size
  • Competitive pressure from better-funded large-cap healthcare companies and new product entrants
  • Operational risk including management execution, manufacturing/partnering delays, or inability to commercialize products

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for CELZ — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.